Arrakis' oral therapies targeting disease-driving RNA in myotonic dystrophy have shown promise in preclinical studies.

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Arrowhead Pharmaceuticals, Inc. today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's second investigational RNA ...

Options Technology, a trailblazer in capital markets infrastructure, would like to congratulate the Tokyo Stock Exchange (TSE) on the successful upgrade to their cash equity trading system, arrowhead ...

Arrowhead will hand over responsibility for the preclinical ... genetic diseases,” said Louise Rodino-Klapac, Sarepta’s chief ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Shares of both Sarepta and Arrowhead are up by more than 10% ... Always ahead of the curve, HCG is spearheading the charge to ...

Sarepta Therapeutics said Tuesday that it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases in the muscle, nervous system ...

From acting advice from Donna Kelce to a pep talk from Kansas City coach Andy Reid, TODAY’s Jenna Bush Hager shares a ...

In just a few years, the city has replaced vast swathes of farmland with sprawling technology parks and scientific facilities, and much of its high-tech industry has moved away from sourcing ...